10 Breakthrough Facts About the Hidden Cancer-Fighting Compound in Tropical Plants

For years, scientists have known that certain tropical plants harbor a rare compound called mitraphylline, which shows promise in fighting cancer. But extracting enough of it for research—let alone treatment—was nearly impossible because the molecule is produced in minuscule amounts. That changed when researchers at UBC Okanagan cracked the code: they identified two enzymes that work together to assemble mitraphylline's unusual twisted structure. This discovery not only solves a long-standing biochemical puzzle but also opens the door to sustainable production. As we'll explore in item 5, this breakthrough could revolutionize how we access nature's pharmacy. Here are 10 things you need to know about this remarkable find.

1. What Is Mitraphylline and Why Does It Matter?

Mitraphylline is a natural alkaloid found in tropical plants such as Mitragyna speciosa (kratom) and Uncaria tomentosa (cat’s claw). Unlike common plant compounds, it has a unique twisted molecular structure that gives it powerful anti-cancer properties in laboratory studies. However, the plant produces only tiny amounts—often less than 0.1% of its dry weight—making large-scale extraction impractical. The new discovery reveals how the plant builds this complex molecule, which is the first step toward creating it in the lab or engineering plants to produce more.

2. The 20-Year Research Puzzle

Scientists have known about mitraphylline since the 1960s, but exactly how plants synthesize it remained a mystery. The compound belongs to a class called monoterpenoid indole alkaloids, which includes well-known drugs like vinblastine (used in chemotherapy) and quinine. The challenge was that mitraphylline has an unusual aza-adamantane core—a cage-like structure rarely seen in nature. For decades, researchers could not find the enzymes responsible for forming this unique ring system. The breakthrough came when the UBC Okanagan team focused on two specific enzymes that catalyze a key step called cyclization.

3. How the Two Enzymes Work Together

The research team identified two enzymes—a strictosidine synthase-like enzyme and a cytochrome P450—that act in sequence. The first enzyme attaches a sugar molecule to a precursor, while the second enzyme folds the molecule into its final twisted shape. Together, they perform a complex chemical reaction that no other known plant enzyme can do. Think of it like a two-person assembly line: one enzyme prepares the raw material, and the other performs the intricate folding. Understanding this partnership is critical for replicating the process in a lab or in other organisms.

4. Why the Twisted Structure Is So Remarkable

The aza-adamantane core of mitraphylline is chemically stable yet biologically active. Its twisted shape allows it to bind tightly to cancer cell proteins, interfering with their ability to divide. This is similar to how some modern cancer drugs work, but mitraphylline is natural and may have fewer side effects. The structure is so unusual that chemists have called it a 'molecular masterwork'—and until now, no one knew how nature built it. The discovery of the enzymes gives scientists the blueprints to design even more potent derivatives.

5. The Promise of Sustainable Production

Currently, collecting enough mitraphylline for research requires harvesting thousands of kilograms of plant material, which is neither sustainable nor scalable. By isolating the two enzymes, scientists can now consider several production methods: (1) growing the enzymes in yeast or bacteria to produce the compound in fermentation tanks, (2) engineering kratom or cat’s claw plants to overexpress the enzymes, or (3) using the enzymes as catalysts in a synthetic chemistry process. Any of these approaches would dramatically reduce the need for wild harvesting.

6. Potential Applications Beyond Cancer

While mitraphylline is primarily studied for anti-cancer effects, it also shows promise in other areas. Early tests suggest it has anti-inflammatory and antiviral properties. Because the aza-adamantane core is similar to structures found in certain drugs for neurological conditions, researchers are also investigating whether mitraphylline or its derivatives could treat Alzheimer's or Parkinson's disease. The enzyme discovery makes it easier to produce enough compound for these wider studies.

7. The Role of UBC Okanagan’s Team

The research was led by Dr. Susan Murch and her colleagues at the University of British Columbia’s Okanagan campus. Their lab specializes in understanding how plants produce medicinal compounds. The team used advanced techniques including transcriptomics (studying which genes are active) and metabolomics (tracking the chemical steps) to pinpoint the two enzymes. Their work was published in a peer-reviewed journal, and they have already filed a patent for the method. This positions UBC Okanagan as a leader in natural product biosynthesis.

8. Challenges Ahead: Scaling Up and Safety

Decoding the biosynthesis is only the first step. Producing mitraphylline in large quantities will require optimizing the enzyme reactions—for instance, making sure the yeast or bacterial cultures produce enough of the precursor molecules. Safety is another concern: while mitraphylline appears selective against cancer cells in lab tests, full clinical trials are years away. The team emphasizes that people should not try to self-medicate with raw kratom or cat’s claw, as these plants contain dozens of other compounds with unknown effects.

9. How This Differs from Previous Research

Earlier studies had identified the overall structure of mitraphylline and even proposed chemical pathways for its synthesis. But nobody had found the actual enzymes that nature uses. This is a crucial distinction: knowing the enzymes allows for biological production (using living cells) rather than purely chemical synthesis, which is often more expensive and environmentally harmful. The UBC Okanagan team’s approach is similar to how the anti-malarial drug artemisinin is now produced using engineered yeast—a method that won a Nobel Prize in 2015.

10. The Future of Plant-Derived Cancer Drugs

This breakthrough could accelerate the development of new cancer therapies derived from plants. Many existing chemotherapies (like paclitaxel from yew trees) come from natural sources but have supply chain problems. The mitraphylline story shows that by understanding plant biochemistry, we can create sustainable sources of rare compounds. The next step is to produce enough for preclinical testing. If successful, mitraphylline could join the growing list of plant-based drugs used in oncology.

In conclusion, the decoding of mitraphylline’s production is a testament to the power of modern genomics and biochemistry. It transforms a rare, almost mythical plant compound into a tangible candidate for drug development. While challenges remain—from scaling up to clinical trials—the discovery gives hope that nature’s most elusive medicines can be made accessible to those who need them most. Keep an eye on this space; the journey from leaf to lab is just beginning.